{
  "nodes": [
    {
      "id": 1,
      "label": "Query__CQURYPUSER",
      "query": "What’s the ripple effect of a government-sponsored universal healthcare system requiring genetic testing for all citizens?"
    },
    {
      "id": 2,
      "label": "What-If Scenario__CQURYFHYSC"
    },
    {
      "id": 5,
      "label": "Key Assumptions__CQURYFHYSS"
    },
    {
      "id": 7,
      "label": "Logical Outcomes__CQURYFHYCN"
    },
    {
      "id": 9,
      "label": "Branching Possibilities__CQURYFHYLT"
    },
    {
      "id": 11,
      "label": "Real-World Takeaway__CQURYFHYMP"
    },
    {
      "id": 13,
      "label": "Baseline Readout__CQURYFHYLTDMMRY"
    },
    {
      "id": 14,
      "label": "Genetic Testing In Public Health__C7YDTPQURY",
      "query": "What happens to the legitimacy of state authority when citizens perceive genetic surveillance as a non-negotiable condition for accessing healthcare?"
    },
    {
      "id": 15,
      "label": "Concrete Instances__CQURYFHYSCDXMPL"
    },
    {
      "id": 16,
      "label": "Genetic Data Trap__C71U1PQURY",
      "query": "What happens if public trust in government deteriorates after the genetic database is established—does the system still hold, or does it accelerate misuse?"
    },
    {
      "id": 17,
      "label": "Regime Transition__CQURYFHYMPDTMPR"
    },
    {
      "id": 18,
      "label": "Genetic Testing In Healthcare__CMCX2PQURY",
      "query": "What happens to public trust in healthcare institutions when genetic risk stratification leads to visibly unequal access within a universal system?"
    },
    {
      "id": 19,
      "label": "The Operative Context__CQURYFHYCNDCNTX"
    },
    {
      "id": 20,
      "label": "Genetic Risk Scores__CL6IWPQURY",
      "query": "What if the perceived value of genetic data in universal healthcare depends not on its current predictive accuracy but on the expectation of future improvements in polygenic risk modeling?"
    },
    {
      "id": 21,
      "label": "What-If Scenario__CL6IWFHYSC"
    },
    {
      "id": 23,
      "label": "Key Assumptions__CL6IWFHYSS"
    },
    {
      "id": 25,
      "label": "Logical Outcomes__CL6IWFHYCN"
    },
    {
      "id": 27,
      "label": "Branching Possibilities__CL6IWFHYLT"
    },
    {
      "id": 29,
      "label": "Real-World Takeaway__CL6IWFHYMP"
    },
    {
      "id": 31,
      "label": "Regime Transition__CL6IWFHYSCDTMPR"
    },
    {
      "id": 32,
      "label": "Genetic Risk Scores Failing__CI8BDPL6IW"
    },
    {
      "id": 33,
      "label": "Schools of Thought__C7YDTFPRSA"
    },
    {
      "id": 35,
      "label": "Ideological Framing__C7YDTFPRDL"
    },
    {
      "id": 37,
      "label": "Cultural Interpretation__C7YDTFPRCL"
    },
    {
      "id": 39,
      "label": "Implicit Framework__C7YDTFPRBS"
    },
    {
      "id": 41,
      "label": "Vested Interest Reasoning__C7YDTFPRSB"
    },
    {
      "id": 43,
      "label": "Baseline Readout__C7YDTFPRBSDMMRY"
    },
    {
      "id": 44,
      "label": "Genetic Testing As Gatekeeper__CWA6GP7YDT",
      "query": "What happens to the legitimacy of state authority when a significant portion of the population refuses genetic testing but still demands access to healthcare?"
    },
    {
      "id": 45,
      "label": "Origins and Triggers__CMCX2FCSRT"
    },
    {
      "id": 47,
      "label": "Causal Mechanisms__CMCX2FCSMC"
    },
    {
      "id": 49,
      "label": "Effects and Outcomes__CMCX2FCSFF"
    },
    {
      "id": 51,
      "label": "Moderating Factors__CMCX2FCSMD"
    },
    {
      "id": 53,
      "label": "Early Signals__CMCX2FCSCR"
    },
    {
      "id": 55,
      "label": "Causal Constraints__CMCX2FCSCS"
    },
    {
      "id": 57,
      "label": "Regime Transition__CMCX2FCSFFDTMPR"
    },
    {
      "id": 58,
      "label": "Genetic Risk Screening__CNPY8PMCX2",
      "query": "What happens to public trust in genetic risk stratification when reclassification occurs so frequently that individuals move between risk tiers without changes in lifestyle or clinical status?"
    },
    {
      "id": 59,
      "label": "Overlooked Angles__CL6IWFHYCNDBLND"
    },
    {
      "id": 60,
      "label": "Genetic Data Value__C7DZCPL6IW",
      "query": "What would happen to public support for genetic data collection if pharmaceutical companies were found to profit from citizen data while clinical benefits remained unproven?"
    },
    {
      "id": 61,
      "label": "What-If Scenario__C71U1FHYSC"
    },
    {
      "id": 63,
      "label": "Key Assumptions__C71U1FHYSS"
    },
    {
      "id": 65,
      "label": "Logical Outcomes__C71U1FHYCN"
    },
    {
      "id": 67,
      "label": "Branching Possibilities__C71U1FHYLT"
    },
    {
      "id": 69,
      "label": "Real-World Takeaway__C71U1FHYMP"
    },
    {
      "id": 71,
      "label": "The Operative Context__C71U1FHYSSDCNTX"
    },
    {
      "id": 72,
      "label": "Genetic Risk Scores__C07WGP71U1"
    },
    {
      "id": 73,
      "label": "What-If Scenario__C7DZCFHYSC"
    },
    {
      "id": 75,
      "label": "Key Assumptions__C7DZCFHYSS"
    },
    {
      "id": 77,
      "label": "Logical Outcomes__C7DZCFHYCN"
    },
    {
      "id": 79,
      "label": "Branching Possibilities__C7DZCFHYLT"
    },
    {
      "id": 81,
      "label": "Real-World Takeaway__C7DZCFHYMP"
    },
    {
      "id": 83,
      "label": "Concrete Instances__C7DZCFHYCNDXMPL"
    },
    {
      "id": 84,
      "label": "Drug Companies Using Public DNA Data__CDGJ6P7DZC"
    },
    {
      "id": 85,
      "label": "What-If Scenario__CWA6GFHYSC"
    },
    {
      "id": 87,
      "label": "Key Assumptions__CWA6GFHYSS"
    },
    {
      "id": 89,
      "label": "Logical Outcomes__CWA6GFHYCN"
    },
    {
      "id": 91,
      "label": "Branching Possibilities__CWA6GFHYLT"
    },
    {
      "id": 93,
      "label": "Real-World Takeaway__CWA6GFHYMP"
    },
    {
      "id": 95,
      "label": "Regime Transition__CWA6GFHYSCDTMPR"
    },
    {
      "id": 96,
      "label": "Genetic Refusal Matters__C9U6PPWA6G"
    },
    {
      "id": 97,
      "label": "Origins and Triggers__CNPY8FCSRT"
    },
    {
      "id": 99,
      "label": "Causal Mechanisms__CNPY8FCSMC"
    },
    {
      "id": 101,
      "label": "Effects and Outcomes__CNPY8FCSFF"
    },
    {
      "id": 103,
      "label": "Moderating Factors__CNPY8FCSMD"
    },
    {
      "id": 105,
      "label": "Early Signals__CNPY8FCSCR"
    },
    {
      "id": 107,
      "label": "Causal Constraints__CNPY8FCSCS"
    },
    {
      "id": 109,
      "label": "Concrete Instances__CNPY8FCSMDDXMPL"
    },
    {
      "id": 110,
      "label": "Genetic Risk Changes__CYO5ZPNPY8"
    },
    {
      "id": 111,
      "label": "Baseline Readout__CNPY8FCSCSDMMRY"
    },
    {
      "id": 112,
      "label": "Genetic Risk Labels__C4SYZPNPY8"
    }
  ],
  "edges": [
    {
      "source": 1,
      "target": 2,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 5,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 7,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 9,
      "relationship": "__anchor__"
    },
    {
      "source": 1,
      "target": 11,
      "relationship": "__anchor__"
    },
    {
      "source": 9,
      "target": 13,
      "relationship": "__anchor__"
    },
    {
      "source": 13,
      "target": 14,
      "relationship": "**Universal genetic testing under public healthcare embeds lifelong surveillance into medical access, shifting the citizen-state relationship by making data sharing a required condition of care.**\n\nWhen a government requires everyone to be genetically screened through public healthcare, it gains access to large amounts of genomic data. This creates a lasting shift in how health systems manage information. Like the UK Biobank within the NHS, collecting genetic data at scale allows the state to expand into predicting health risks. Testing becomes routine, so people cannot easily refuse. This makes data collection a built-in part of receiving medical care. Over time, health agencies build strong systems to sort people by genetic risk. These systems operate without needing consent. They affect decisions about reproduction, insurance, and family health. The setup resembles national immunization registries but goes much deeper. Genetic data becomes central to who gets care and how. As a result, access to health services depends on submitting to genetic monitoring. Medical citizenship now means being genetically visible to the state."
    },
    {
      "source": 2,
      "target": 15,
      "relationship": "__anchor__"
    },
    {
      "source": 15,
      "target": 16,
      "relationship": "**Mandatory genetic testing in universal healthcare creates permanent surveillance risk because data collection outlasts consent and spreads beyond clinical use.**\n\nIn a universal healthcare system, requiring genetic testing creates a state-controlled database of population-wide genetic information. This collection happens even when individuals cannot freely consent. The state collects data as both healthcare provider and administrator. Clinical records become a source of administrative data. Once genetic data enters the system, it cannot be deleted. There is no way to limit how the data is used later. Even if current laws block misuse, the data can still be used by insurers, employers, or police in the future. Iceland’s deCODE program shows this risk. Its national biobank faced disputes over access by private and research groups. A universal system with mandatory testing removes the barrier between medical care and data surveillance. The combination of compulsory data submission and permanent storage creates a lasting infrastructure for monitoring. No individual opt-out can undo this structural shift once the system is in place."
    },
    {
      "source": 11,
      "target": 17,
      "relationship": "__anchor__"
    },
    {
      "source": 17,
      "target": 18,
      "relationship": "**Universal genetic testing in a national health system shifts from prevention to discrimination when data collection overwhelms medical usefulness, replacing fairness with probabilistic exclusion.**\n\nA government program that requires universal genetic testing in a national health system risks creating a new form of biological sorting. This sorting uses actuarial logic instead of clinical judgment to decide who gets medical care. The shift grows stronger as the state expands its control over health. It reaches a limit when data collection becomes more important than medical usefulness. At that point, the program changes from preventing disease to discriminating against people. As genetic databases grow, the system moves from preventing sickness in the population to rating risk and limiting access. This mirrors how insurance companies used predictive genetics to redefine preexisting conditions. The system works only as long as genetic information is medically useful and socially controlled. Once data becomes too dense and genetic traits too complex, the system weakens. This is shown by the falling results of large genetic studies in the 2010s. Finally, the system replaces fairness with exclusion based on probability."
    },
    {
      "source": 7,
      "target": 19,
      "relationship": "__anchor__"
    },
    {
      "source": 19,
      "target": 20,
      "relationship": "**Genetic risk scores cannot reliably guide healthcare because current data show they lack the predictive power needed to foresee common diseases.**\n\nState health systems are building large genetic databases to guide medical care based on inherited disease risk. These plans depend on using genetic data to sort patients by future illness likelihood. Scientists calculate this risk using polygenic risk scores. However, most research shows these scores cannot reliably predict common diseases. This is true especially for people from different ethnic backgrounds. The scores fail because genes alone explain little about disease development. Environmental factors and lifestyle matter greatly. Also, gene effects are small and hard to measure accurately. Long-term data show the scores do not predict conditions like diabetes or heart disease well. Without strong prediction, care based on genetic risk makes little sense. The idea only works if predictions are accurate. Current evidence shows they are not. So, shifting medical decisions to genetic risk is not supported now."
    },
    {
      "source": 20,
      "target": 21,
      "relationship": "__anchor__"
    },
    {
      "source": 20,
      "target": 23,
      "relationship": "__anchor__"
    },
    {
      "source": 20,
      "target": 25,
      "relationship": "__anchor__"
    },
    {
      "source": 20,
      "target": 27,
      "relationship": "__anchor__"
    },
    {
      "source": 20,
      "target": 29,
      "relationship": "__anchor__"
    },
    {
      "source": 21,
      "target": 31,
      "relationship": "__anchor__"
    },
    {
      "source": 31,
      "target": 32,
      "relationship": "**Genetic risk scores are not improving enough to be useful in health care because they fail to capture how genes interact with environment and rare variants, so their value depends on hope, not results.**\n\nLarge health databases now include genetic data from millions of people. These databases assume that genetic risk scores will improve enough to guide medical care. The hope is that scores will predict disease risk accurately across all groups. But data show that improvement has slowed. Scores still cannot predict most diseases well. This is especially true for non-European groups. The main reasons are poor understanding of how genes interact with environment and lifestyle. Rare gene variants also remain hard to measure. Despite this, officials keep treating genetic data as highly valuable. This belief continues only because few demand proof of real-world accuracy. Once policies require proven results, the optimism will not be enough. The value of genetic data rests on hope, not on current evidence. The data have not yet delivered reliable predictions for health care."
    },
    {
      "source": 14,
      "target": 33,
      "relationship": "__anchor__"
    },
    {
      "source": 14,
      "target": 35,
      "relationship": "__anchor__"
    },
    {
      "source": 14,
      "target": 37,
      "relationship": "__anchor__"
    },
    {
      "source": 14,
      "target": 39,
      "relationship": "__anchor__"
    },
    {
      "source": 14,
      "target": 41,
      "relationship": "__anchor__"
    },
    {
      "source": 39,
      "target": 43,
      "relationship": "__anchor__"
    },
    {
      "source": 43,
      "target": 44,
      "relationship": "**Health care access tied to genetic data makes surveillance unavoidable because the state gains power by defining normal biology through routine data collection.**\n\nIn some countries, getting health care now requires sharing genetic data. This data helps the state decide who is at biological risk. Over time, this makes genetic testing routine, not optional. Medical care becomes linked to genetic surveillance. Refusing tests can mean losing access to care. The state decides what counts as normal biology. Those who refuse are seen as unfit to be patients. Compliance becomes the price of medical belonging. Citizenship is shown by data sharing. Not complying becomes invisible to the system. Authority grows by making resistance seem irrational."
    },
    {
      "source": 18,
      "target": 45,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 47,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 49,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 51,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 53,
      "relationship": "__anchor__"
    },
    {
      "source": 18,
      "target": 55,
      "relationship": "__anchor__"
    },
    {
      "source": 49,
      "target": 57,
      "relationship": "__anchor__"
    },
    {
      "source": 57,
      "target": 58,
      "relationship": "**Genetic risk screening loses public trust at scale because broader data weakens prediction accuracy, turning equitable care into perceived exclusion.**\n\nPredictive genetic screening can change how medical care is allocated. It shifts focus from current health needs to forecasts of future risk. This creates tiers of access that seem fair but harm high-risk groups. The system works best when genetic data is clear and limited. Early programs, like those for BRCA, showed clear benefits. Risks were easy to define. Care was still reachable. But as data grows, the predictions become less reliable. This happens with models for complex traits. Risk groups get redefined often. The system loses credibility. People see access rules as random, not medical. High-risk, healthy people get denied care. This sparks distrust. The problem grows when prevention feels like denial. The system isn't corrupt. It just fails to stay consistent. As genetic data scales up, the logic breaks. What once helped now excludes."
    },
    {
      "source": 25,
      "target": 59,
      "relationship": "__anchor__"
    },
    {
      "source": 59,
      "target": 60,
      "relationship": "**Genetic data remains valuable because its worth is tied to long-term research and drug development, not to immediate clinical success.**\n\nNational healthcare systems often collect genetic data for biobanks. They do not rely solely on how well genes predict disease. Even if gene-based disease scores improve slowly, the data remains valuable. This is because the data serves more than just clinical uses. Projects like UK Biobank and All of Us gather genetic information for many purposes. These include drug development and discovering disease types. Small genetic links can still help research and lead to new treatments. The real value lies in using data as a resource over time. Public and private groups share this data to drive innovation. It is treated as a long-term asset. This system stays strong even if medical uses are limited now. The reason is simple: success is not measured by patient care alone. Instead, value comes from building tools and discoveries over decades. So, genetic programs keep growing. Their worth does not depend on immediate medical proof. They are tied to goals beyond the clinic. Thus, doubts about prediction accuracy do not stop data collection. The main reason for gathering data is not short-term medical benefit. It is long-term research and commercial potential."
    },
    {
      "source": 16,
      "target": 61,
      "relationship": "__anchor__"
    },
    {
      "source": 16,
      "target": 63,
      "relationship": "__anchor__"
    },
    {
      "source": 16,
      "target": 65,
      "relationship": "__anchor__"
    },
    {
      "source": 16,
      "target": 67,
      "relationship": "__anchor__"
    },
    {
      "source": 16,
      "target": 69,
      "relationship": "__anchor__"
    },
    {
      "source": 63,
      "target": 71,
      "relationship": "__anchor__"
    },
    {
      "source": 71,
      "target": 72,
      "relationship": "**Genetic risk scores lose public trust when their predictions are less accurate for certain groups, making fair-seeming systems appear discriminatory and causing rejection of public health efforts.**\n\nPublic health systems now use genetic data to predict who is at risk for certain diseases. These predictions guide who gets preventive care. But the systems only work if people believe they are fair and accurate. Trust breaks down when the predictions do not work equally well for everyone. Polygenic risk scores, which estimate disease likelihood, often perform worse for non-European groups. This happens because most genetic research has focused on people of European descent. As a result, scores vary by ancestry, sex, and social background. When high-risk people are denied care because they show no symptoms, they see the system as arbitrary. Programs in Finland and the U.S. have shown that weak predictions damage credibility. People start to feel excluded, not protected. Trust collapses when models fail across groups. Fairness and accuracy across populations are essential. Without them, the system looks discriminatory. This leads people to disengage when their cooperation is most needed."
    },
    {
      "source": 60,
      "target": 73,
      "relationship": "__anchor__"
    },
    {
      "source": 60,
      "target": 75,
      "relationship": "__anchor__"
    },
    {
      "source": 60,
      "target": 77,
      "relationship": "__anchor__"
    },
    {
      "source": 60,
      "target": 79,
      "relationship": "__anchor__"
    },
    {
      "source": 60,
      "target": 81,
      "relationship": "__anchor__"
    },
    {
      "source": 77,
      "target": 83,
      "relationship": "__anchor__"
    },
    {
      "source": 83,
      "target": 84,
      "relationship": "**Public support for DNA data collection stays strong because its value is tied to early drug research, not proven health benefits.**\n\nPublic-private partnerships in genetic research often rely on models where drug companies help fund and access large biobanks. These collaborations, like the UK Biobank’s work with AstraZeneca and GlaxoSmithKline, treat genetic data as a starting point for drug discovery. The value of this data comes from its use in early research, not from proving patient benefits. Policies such as the Genomic Data Sharing rule and the All of Us program support sharing data with industry. These frameworks keep public trust stable even when medical results are not guaranteed. Drug firms continue to invest in repurposing genetic data for new targets and biomarkers. Because the system treats genetic data as a basic research tool, public support does not depend on immediate health outcomes."
    },
    {
      "source": 44,
      "target": 85,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 87,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 89,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 91,
      "relationship": "__anchor__"
    },
    {
      "source": 44,
      "target": 93,
      "relationship": "__anchor__"
    },
    {
      "source": 85,
      "target": 95,
      "relationship": "__anchor__"
    },
    {
      "source": 95,
      "target": 96,
      "relationship": "**When large groups refuse genetic screening, healthcare systems lose confidence in population data, forcing states to recognize refusal as legitimate dissent rather than error.**\n\nUniversal healthcare systems rely on complete data to manage population health. When genetic screening becomes routine, participation supports accurate risk assessment for all. Refusing genetic tests can disrupt how care is planned and funded. In the UK Biobank and NHS partnership, data gaps from refusals undermine statistical models. Medical legitimacy increasingly depends on full data, not personal choice. As more people decline testing, they form a visible group rather than random outliers. This shift forces states to treat refusals as meaningful dissent. The EU’s privacy laws began treating such acts as legal concerns, not errors. When refusal is seen as collective, the state can no longer ignore it. Healthcare no longer rests on total data control. Authority shifts from command to negotiation. Universal genetic submission loses force when people act together."
    },
    {
      "source": 58,
      "target": 97,
      "relationship": "__anchor__"
    },
    {
      "source": 58,
      "target": 99,
      "relationship": "__anchor__"
    },
    {
      "source": 58,
      "target": 101,
      "relationship": "__anchor__"
    },
    {
      "source": 58,
      "target": 103,
      "relationship": "__anchor__"
    },
    {
      "source": 58,
      "target": 105,
      "relationship": "__anchor__"
    },
    {
      "source": 58,
      "target": 107,
      "relationship": "__anchor__"
    },
    {
      "source": 103,
      "target": 109,
      "relationship": "__anchor__"
    },
    {
      "source": 109,
      "target": 110,
      "relationship": "**Public trust in genetic risk prediction falls when people are repeatedly reclassified without health changes, because small data updates shift their risk group in ways that seem arbitrary and unexplained.**\n\nNational health systems that use genetic data to predict disease risk face a problem when they rely on polygenic scores. These scores combine many small genetic effects to estimate a person’s risk. Because each variant has a tiny impact, the overall score can shift with small updates to population data. This causes people to move in and out of risk groups without any change in their health or habits. For example, someone might qualify for preventive treatment one year and not the next. These shifts happen due to statistical noise, not real health changes. When access to care keeps changing, people lose trust. They see the decisions as arbitrary and unclear. This does not happen as much with single-gene tests, where results are more stable and clearly linked to disease. In those cases, risk labels stay the same over time. Public trust drops when genetic risk categories keep changing without a clear medical reason. The loss of confidence is specific to systems using polygenic scores, not simpler genetic tests."
    },
    {
      "source": 107,
      "target": 111,
      "relationship": "__anchor__"
    },
    {
      "source": 111,
      "target": 112,
      "relationship": "**Public trust declines when genetic risk labels change often because unstable categories make access to care seem arbitrary and unfair.**\n\nLarge healthcare systems sometimes use genetic data to predict who is most at risk for certain diseases. These predictions can guide who gets preventive care. But when the genetic risk scores change frequently, people lose trust. This happens not because the predictions cause direct harm, but because shifting risk levels make access to care seem arbitrary. The problem grows when methods that work well for rare gene mutations are used for complex traits influenced by many genes. In real-world programs like UK Biobank and FinnGen, these genetic risk scores often shift due to statistical noise and differences across populations. As a result, people may be moved in and out of risk categories without any real change in health. This makes medical access feel like a lottery, not a right. When people are denied care based on unstable genetic labels, they see the system as unfair. Trust drops, especially when these labels change often and do not lead to clear actions. Public trust falls not because data is misused, but because the system relies on unstable categories."
    }
  ],
  "query": "What’s the ripple effect of a government-sponsored universal healthcare system requiring genetic testing for all citizens?"
}